SGLT2 Inhibitors Improve Left Ventricular Diastolic Dysfunction in Patients with Type 2 Diabetes: A Narrative Review of Mechanistic and Clinical Evidence

Q: What are the key findings of this study?

SGLT2 inhibitors improve left ventricular diastolic dysfunction in type 2 diabetes by reducing lipotoxicity, inflammation, oxidative stress, and optimizing hemodynamics.

Q: What is the clinical evidence from this study?

Study design: Review. Population: Type 2 diabetes mellitus complicated by left ventricular diastolic dysfunction. Intervention: Sodium-glucose co-transporter-2 inhibitors (SGLT2i) vs. Control or standard care. Primary outcome: Left ventricular diastolic function and echocardiographic indices (e.g., E/e' ratio, LAVi, LVMi).

Q: What does this research mean for the field?

SGLT2 inhibitors improve left ventricular diastolic dysfunction in patients with type 2 diabetes by reducing myocardial lipotoxicity, attenuating inflammation and oxidative stress, improving endothelial function, and optimizing hemodynamics. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

则涛 关

doi:10.12677/acm.2026.16113613

January 1, 2026Advances in Clinical MedicineOpen Access

SGLT2 Inhibitors Improve Left Ventricular Diastolic Dysfunction in Patients with Type 2 Diabetes: A Narrative Review of Mechanistic and Clinical Evidence

View Full Paper

Ask AI

Bookmark

Share

Key result

SGLT2 inhibitors improve LV diastolic function in type 2 diabetes across multiple cardioprotective mechanisms.

Why the study?

Most patients with T2DM and echocardiographically diagnosed left ventricular diastolic dysfunction are currently managed with close observation and no intervention, and clinical and basic research on SGLT2 inhibitors needed synthesis to provide a theoretical basis for treatment.

Key Points

To synthesize mechanistic and clinical evidence evaluating how sodium-glucose co-transporter-2 (SGLT2) inhibitors improve left ventricular diastolic dysfunction in patients with type 2 diabetes mellitus.
Conducted a narrative review searching PubMed using terms including 'sodium-glucose co-transporter-2 inhibitors', 'SGLT2i', 'type 2 diabetes mellitus', and 'left ventricular diastolic dysfunction'.
Synthesized molecular mechanistic evidence, preclinical studies, meta-analyses, and clinical trials examining cardiac remodeling and hemodynamic parameters.
Mechanistic data show SGLT2 inhibitors reduce myocardial lipotoxicity, attenuate oxidative stress and NLRP3 inflammasome activation, improve nitric oxide bioavailability, and optimize loading conditions.
A cited meta-analysis of 32 studies (n=2351) found SGLT2 inhibitors significantly reduced left ventricular mass index (MD -3.99, 95% CI -7.16 to -0.82, P=0.01), left atrial volume index (MD -1.77, 95% CI -2.97 to -0.57, P<0.01), and E/e' ratio (MD -1.39, 95% CI -2.04 to -0.73, P<0.01).
Evidence remains mixed in broader cohorts, highlighting the need for large-scale, long-term randomized controlled trials to determine precise intervention thresholds and duration of benefits.

PICO

P

Population

Patients with type 2 diabetes mellitus and left ventricular diastolic dysfunction synthesized across clinical trials, meta-analyses, and mechanistic studies.

I

Intervention / Comparator

Sodium-glucose co-transporter-2 inhibitors (SGLT2i) vs Control or standard care

O

Primary Outcome

Left ventricular diastolic function and echocardiographic indices (e.g., E/e' ratio, LAVi, LVMi)

Limitations

Lack of large-scale, long-term, multicenter randomized controlled trials with left ventricular diastolic function as the primary endpoint
Unclear intervention threshold and whether effects attenuate or reverse over time or after drug discontinuation
Inconsistency in primary endpoint definitions (e.g., E/e' ratio, LVGLS, ECV, EAT thickness) across existing studies
Many mechanistic and clinical findings rely on animal models or small, open-label, non-randomized studies
Insufficient evidence on whether benefits vary across the three grades of diastolic dysfunction or are independent of blood pressure, weight, and glycemic improvements

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

May support SGLT2 inhibitor selection in T2D with diastolic dysfunction; leaves open dedicated outcome trials.

Abstract

暨南大学附属第一医院，

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

则涛关 (2026) conducted a review in Type 2 diabetes mellitus complicated by left ventricular diastolic dysfunction. Sodium-glucose co-transporter-2 inhibitors (SGLT2i) vs. Control or standard care was evaluated on Left ventricular diastolic function and echocardiographic indices (e.g., E/e' ratio, LAVi, LVMi). SGLT2 inhibitors improve left ventricular diastolic dysfunction in type 2 diabetes by reducing lipotoxicity, inflammation, oxidative stress, and optimizing hemodynamics.

synapsesocial.com/papers/6af0e999de503f3774140a14 https://doi.org/10.12677/acm.2026.16113613

View Full Paper

Ask AI

Bookmark

Share

SGLT2 Inhibitors Improve Left Ventricular Diastolic Dysfunction in Patients with Type 2 Diabetes: A Narrative Review of Mechanistic and Clinical Evidence

Key Points

PICO

Limitations

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

SGLT2 Inhibitors Improve Left Ventricular Diastolic Dysfunction in Patients with Type 2 Diabetes: A Narrative Review of Mechanistic and Clinical Evidence

Key Points

PICO

Limitations

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading